The Food and Drug Administration (FDA) has approved Blenrep (belantamab mafodotin-blmf) in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory ...

GSK announced FDA’s approval of Blenrep in combination with bortezomib and dexamethasone (BVd) for the treatment of adults diagnosed with relapsed or refractory multiple myeloma who received a minimum ...

BLENREP is indicated in combination with bortezomib and dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least two prior lines of ...

A dexamethasone-sparing regimen involving lenalidomide (Revlimid) and the anti-CD38 drug daratumumab (Darzalex) was safe and effective in older, frail patients with newly diagnosed multiple myeloma, ...

The article by Ailawadhi et al titled “Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III ...

Antiviral remdesivir should not be used as a routine treatment for COVID-19 patients in critical care wards, the head of one of the world's top bodies representing intensive care doctors said, in a ...

A World Health Organization-led scheme to supply COVID-19 drugs to poor countries is betting on experimental monoclonal antibody treatments and steroids but shunning Gilead's remdesivir therapy, an ...